3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Prostatic Neoplasms
58
Breast Neoplasms
25
Neoplasms
5
Neoplasm Metastasis
3
Leiomyoma
3
Polycystic Ovary Syndrome
2
Neoplasms by Site
2
Endometrial Neoplasms
2
Cardiovascular Diseases
2
Breast Diseases
2
Stage II Prostate Adenocarcinoma
1
Sleep Wake Disorders
1
Skin Diseases
1
Sexual Dysfunctions, Psychological
1
Salivary Gland Neoplasms
1
Salivary Gland Adenoma, Pleomorphic
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatectomy
1
Prostate Cancer With ≤10 Bone Metastases
1
Prostate Cancer Metastatic Disease
1
Prostate Cancer Metastatic
1
Pelvic Pain
1
Ovarian Neoplasms
1
Osteoporosis
1
Oligometastatic Prostate Carcinoma
1
Metastatic Neuroendocrine Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration-Resistant Prostate Cancer
1
Kallmann Syndrome
1
Inflammatory Breast Neoplasms
1
Interventions
Paclitaxel
326
Carboplatin
318
Bevacizumab
167
Gemcitabine
106
pembrolizumab
101
liposomal doxorubicin
100
Cyclophosphamide
96
Topotecan
93
Cisplatin
89
olaparib
86
niraparib
60
Docetaxel
56
Taxes
52
Doxorubicin
50
Drug Therapy
42
fludarabine
40
Filgrastim
39
Nivolumab
37
Etoposide
32
Specimen Handling
31
Magnetic Resonance Spectroscopy
29
Immunoglobulin G
27
Disulfides
27
Peripheral Blood Stem Cell Transplantation
26
Albumin-Bound Paclitaxel
25
durvalumab
24
aldesleukin
24
Hyperthermic Intraperitoneal Chemotherapy
24
Oxaliplatin
23
Biopsy
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Ovarian Neoplasms
×
Gonadotropin-Releasing Hormone
×
Clear all
NCT04931342
2026-03-10
BOUQUET
Hoffmann-La Roche
Phase 2
Active not recruiting
176 enrolled